GlycoMimetics, Inc. Expected to Post FY2026 Earnings of $0.14 Per Share (NASDAQ:GLYC)

GlycoMimetics, Inc. (NASDAQ:GLYC) – Investment analysts at HC Wainwright issued their FY2026 earnings estimates for shares of GlycoMimetics in a research report issued on Wednesday, March 27th. HC Wainwright analyst E. White anticipates that the biotechnology company will post earnings of $0.14 per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for GlycoMimetics’ current full-year earnings is ($0.60) per share.

Several other research firms have also recently commented on GLYC. Capital One Financial restated an “overweight” rating on shares of GlycoMimetics in a research report on Thursday, February 22nd. StockNews.com lowered shares of GlycoMimetics from a “hold” rating to a “sell” rating in a research note on Thursday, March 14th.

GlycoMimetics Stock Performance

GLYC opened at $3.18 on Thursday. The company has a 50-day moving average of $3.00 and a 200-day moving average of $2.18. The company has a market capitalization of $204.95 million, a P/E ratio of -5.05 and a beta of 2.19. GlycoMimetics has a 1-year low of $1.11 and a 1-year high of $3.53.

Institutional Trading of GlycoMimetics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC purchased a new stake in shares of GlycoMimetics in the 1st quarter valued at approximately $30,000. Acuta Capital Partners LLC acquired a new position in GlycoMimetics in the 3rd quarter valued at approximately $41,000. XTX Topco Ltd acquired a new position in GlycoMimetics in the 2nd quarter valued at approximately $52,000. Charles Schwab Investment Management Inc. acquired a new position in shares of GlycoMimetics during the 4th quarter worth $68,000. Finally, Jane Street Group LLC acquired a new position in shares of GlycoMimetics during the 4th quarter worth $75,000. 75.19% of the stock is owned by institutional investors and hedge funds.

GlycoMimetics Company Profile

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.